李昀纾,罗素新,黄毕

• 1:重庆医科大学附属第一医院心血管内科
• 2:阳光融和医院临床营养科

摘要(Abstract)：

肥厚型心肌病（HCM）是最常见的遗传性心血管病之一，也是青少年心源性猝死的最常见原因之一。HCM的主要病因是肌原纤维蛋白或其相关结构蛋白基因突变，导致室间隔发生不对称性肥厚，约70%的患者出现左心室流出道梗阻（LVOTO），因此可将HCM分为梗阻性和非梗阻性两大类型。梗阻性HCM通过药物或介入治疗可有效降低LVOTO程度。近年来，梗阻性HCM在侵入性治疗方面取得了重要突破，使其成为首个能够基于疾病基因与发病机制实施精准治疗的心血管病。本文对近年来梗阻性HCM在介入治疗领域的研究进展进行综述，以期为临床实践提供参考。

关键词(KeyWords)： 梗阻性肥厚型心肌病;经皮腔内室间隔心肌消融;酒精室间隔消融术;射频消融;CARTOSound技术

Abstract:

Keywords:

基金项目(Foundation): 重庆医科大学2022年未来医学青年创新团队发展支持计划项目（W0184）;; 重庆医科大学附属第一医院研究生教育教学改革研究项目（CYYY-YJSJGXM-202409）

作者(Author): 李昀纾,罗素新,黄毕

参考文献(References)：

• [1] Ommen SR,Ho CY,Asif IM,et al.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy:a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines[J].Circulation,2024,149(23):e1239-e1311.DOI:10.1161/CIR.0000000000001250.
• [2]Marian AJ.Molecular genetic basis of hypertrophic cardiomyopathy[J].Circ Res,2021,128(10):153 3-1553.DOI:10.1161/CIRCRESAHA.121.318346.
• [3]Maron BJ,Desai MY,Nishimura RA,et al.Diagnosis and evaluation of hypertrophic cardiomyopathy:JACC state-of-the-art review[J].J Am Coll Cardiol,2022,79(4):372-389.DOI:10.1016/j.jacc.2021.12.002.
• [4] Maron MS,Olivotto I,Betocchi S,et al.Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy[J].N Engl J Med,2003,348(4):295-303.DOI:10.1056/NEJMoa021332.
• [5]O'Mahony C,Jichi F,Pavlou M,et al.A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy(HCM risk-SCD)[J].Eur Heart J,2014,35(30):2010-2020.DOI:10.1033/heartheartj/eht439.
• [6]Sigwart U.Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J].Lancet,1995,346(8969):211-214.DOI:10.1016/S0140-6736(95)91267-3.
• [7]Baggish AL,Smith RN,Palacios I,et al.Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J].Heart,2006,92(12):1773-1778.DOI:10.1136/hrt.2006.092007.
• [8]刘蓉,乔树宾,胡奉环,等.肥厚型心肌病化学消融术疗效与冠状动脉特点的相关性研究[J].中国介入心脏病学杂志,2016,24(6):311-315.DOI:10.3969/j.issn.1004-8812.2016.06.003.
• [9]Sorajja P,Ommen SR,Holmes DR Jr,et al.Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].Circulation,2012,126(20):2374-23 80.DOI:10.1161/CIRCULATIONAHA.111.076257.
• [10]Sorajja P,Valeti U,Nishimura RA,et al.Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].Circulation,2008,118(2):13 1-139.DOI:10.1161/CIRCULATIONAHA.107.738740.
• [11] Yoerger DM,Picard MH,Palacios IF,et al.Time course of pressure gradient response after first alcohol septalablation for obstructive hypertrophic cardiomyopathy[J].Am J Cardiol,2006,97(10):1511-1514.DOI:10.1016/j.amjcard.2005.12.040.
• [12]Veselka J,Faber L,Liebregts M,et al.Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy[J].Int J Cardiol,2021,333:127-132.DOI:10.1016/j.ijcard.2021.02.056.
• [13] Lu M,Du H,Gao Z,et al.Predictors of outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy:an echocardiography and cardiovascular magnetic resonance imaging study[J].Circ Cardiovasc Interv,2016,9(3):e002675.DOI:10.1161/CIRCINTERVENTIONS.115.002675.
• [14]Bourque C,Réant P,Bernard A,et al.Comparison of surgical ventricular septal reduction to alcohol septal ablation therapy in patients with hypertrophic cardiomyopathy[J].Am J Cardiol,2022,172:109-114.DOI:10.1016/j.amjcard.2022.02.03 3.
• [15]Valeti US,Nishimura RA,Holmes DR,et al.Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy[J].J Am Coll Cardiol,2007,49(3):350-357.DOI:10.1016/j.jacc.2006.08.055.
• [16]Olivotto I,Ommen SR,Maron MS,et al.Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy:will there ever be a randomized trial?[J].J Am Coll Cardiol,2007,50(9):831-834.DOI:10.1016/j.jacc.2007.05.018.
• [17]Siskin GP,Englander M,Stainken BF,et al.Embolic agents used for uterine fibroid embolization[J].AJR Am J Roentgenol,2000,175(3):767-773.DOI:10.2214/ajr.175.3.1750767.
• [18]Gross CM,Schulz-Me nger J,Kr??mer J,et al.Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy:acute and 3-year outcomes[J].J Endovasc Ther,2004,11(6):705-711.DOI:10.1583/03-1171MR.1.
• [19]Durand E,Mousseaux E,Coste P,et al.Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy:early and 6 months follow-up[J].Eur Heart J,2008,29(3):348-355.DOI:10.1093/eurheartj/ehm632.
• [20]Iacob M,Pinte F,Tintoiu I,et al.Microcoil embolization for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy[J].EuroIntervention,2005,1(1):93-97.
• [21]Guerrero I,Doble A,Fasulo M,et al.Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy[J].Catheter Cardiovasc Interv,2016,88(6):971-977.DOI:10.1002/ccd.26668.
• [22]Wu B,Zhou Y,Lu J,et al.Interventricular septal hematoma caused by percutaneous intramyocardial septal radiofrequency ablation successfully treated with coil embolization[J].JACC Cardiovasc Interv,2023,16(6):722-724.DOI:10.1016/j.jcin.2022.10.038.
• [23]Matos GF,Hammadeh R,Francois C,et al.Controlled myocardial infarction induced by intracoro nary inj ection of n-butyl cyanoacrylate in dogs:a feasibility study[J].Catheter Cardiovasc Interv,2005,66(2):244-253.DOI:10.1002/ccd.20486.
• [24] Oto A,Aytemir K,Deniz A.New approach to septal ablation:glue(cyanoacrylate)septal ablation[J].Catheter Cardiovasc Interv,2007,69(7):1021-1025.DOI:10.1002/ccd.21003.
• [25]Okutucu S,Aytemir K,Oto A.Glue septal ablation:a promising alternative to alcohol septal ablation[J].JRSM Cardiovasc Dis,2016,5:2048004016636313.DOI:10.1177/2048004016636313.
• [26]Miyayama S,Yamakado K,Anai H,et al.Guidelines on the use of gelatin sponge particles in embolotherapy[J].Jpn J Radiol,2014,32(4):242-250.DOI:10.1007/s11604-014-0292-2.
• [27]Jenkins HP,Janda R.Studies on the use of gelatin sponge or foam as an hemostatic agent in experimental liver resections and injuries to large veins[J].Ann Surg,1946,124:952-961.
• [28]Ishimori S,Hattori M,Shibata Y,et al.Treatment of carotid-cavernous fistula by gelfoam embolization[J].J Neurosurg,1967,27(4):315-319.DOI:10.3171/jns.1967.27.4.0315.
• [29]Abada HT,Golzarian J.Gelatine sponge particles:handling characteristics for endovascular use[J].Tech Vasc Interv Radiol,2007,10(4):257-260.DOI:10.1053/j.tvir.2008.03.002.
• [30] Sonomura T,Yamada R,Kishi K,et al.Dependency of tissue necrosis on gelatin sponge particle size after canine hepatic artery embolization[J].Cardiovasc Intervent Radiol,1997,20(1):50-53.DOI:10.1007/s002709900108.
• [31]Llamas-Esperón GA,Sandoval-Navarrete S.Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy[J].Catheter Cardiovasc Interv,2007,69(2):231-235.DOI:10.1002/ccd.20935.
• [32]唐炯,张黎,齐峰,等.明胶海绵化学消融治疗5例肥厚型梗阻性心肌病的有效性与安全性分析[J].中国循环杂志,2019,34(12):1181-1185.DOI:10.3969/j.issn.1000-3614.2019.12.007.
• [33]Latsios G,Gerckens U,Mueller R,et al.Substitution of ethanol with specially designed microspheres in a TASH procedure[J].Euro Intervention,2011,6(7):889-892.DOI:10.4244/EIJV6I7A151.
• [34]Alyaydin E,Jánosi RA,Luedike P,et al.Septal microsphere embolization in hypertrophic obstructive cardiomyopathy[J].Am J Cardiol,2023,201:116-122.DOI:10.1016/j.amjcard.2023.06.006.
• [35]林国钦,林俊敏,翁志成,等.微球室间隔消融术治疗梗阻性肥厚型心肌病1例术后4年随访[J].中国介入心脏病学杂志,2022,30(3):228-230.DOI:10.3969/j.issn.1004-8812.2022.03.013.
• [36]陈扬,刘洪序,陈浩,等.射频消融治疗梗阻性肥厚型心肌病有效性及安全性的系统评价和Meta分析[J].中国介入心脏病学杂志,2022,30(12):940-949.DOI:10.3969/j.issn.1004-8812.2022.12.009.
• [37]Lawrenz T,Kuhn H.Endocardial radiofrequency ablation of septal hypertrophy:a new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy[J].Z Kardiol,2004,93(6):493-499.DOI:10.1007/s00392-004-0097-x.
• [38]Lawrenz T,Borchert B,Leuner C,et al.Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy:acute results and 6 months'follow-up in 19patients[J].J Am Coll Cardiol,2011,57(5):572-576.DOI:10.1016/j.j acc.2010.07.055.
• [39]Jiang T,Huang B,Huo S,et al.Endocardial radiofrequency ablation vs.septal myectomy in patients with hypertrophic obstructive cardiomyopathy:a systematic review and meta-analysis[J].Front Surg,2022,9:859205.DOI:10.3389/fsurg.2022.859205.
• [40]贾玉和,林瑶,刘俊,等.在心内三维超声指导下经皮心内膜室间隔射频消融术治疗肥厚型梗阻性心肌病合并晕厥的临床应用研究[J].中国循环杂志,2020,35(7):638-644.DOI:10.3969/j.issn.1000-3614.2020.07.003.
• [41]Cooper RM,Shahzad A,Hasleton J,et al.Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy:a novel use of CARTOSound??technology to guide ablation[J].Europace,2016,18(1):113-120.DOI:10.1093/europace/euv302.
• [42]Chu E,Fitzpatrick AP,Chin MC,et al.Radiofrequency catheter ablation guided by intracardiac echocardiography[J].Circulation,1994,89(3):1301-1305.DOI:10.1161/01.cir.893.1301.
• [43]Cooper RM,Shahzad A,Newton J,et al.Intra-cardiac echocardiography in alcohol septal ablation:a prospective comparative study against trans-thoracic echocardiography[J].Echo Res Pract,2015,2(1):9-17.DOI:10.1530/ERP-15-0002.
• [44]蒋周芩,舒茂琴,柴虹,等.CARTOSound引导下射频消融治疗肥厚型梗阻性心肌病患者的临床效果[J].第三军医大学学报,2021,43(8):736-740.DOI:10.16016/j.1000-5404.202009168.
• [45] Zhou M,Ta S,Hahn RT,et al.Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy[J].JAMA Cardiol,2022,7(5):529-538.DOI:10.1001/jamacardio.2022.0259.
• [46]Liu L,Li J,Zuo L,et al.Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J].J Am Coll Cardiol,2018,72(16):1898-1909.DOI:10.1016/j.jacc.2018.07.080.
• [47]Xie X,Chen S,Cui Y,et al.Midterm outcomes of percutaneous intramyocardial septal radiofrequency ablation for hypertrophic cardiomyopathy:a single-center,observational study[J].J Am Heart Assoc,2024,13(15):e034080.DOI:10.1161/JAHA.123.034080.
• [48] Ta S,Li J,Hsi DH,et al.Percutaneous intramyocardial septal radiofrequency ablation after 5-year follow-up[J].Heart,2024,110(11):792-799.DOI:10.1136/heartjnl-2023-323606.
• [49]国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会“中国成人肥厚型心肌病诊断与治疗指南2023”专家组.中国成人肥厚型心肌病诊断与治疗指南2023[J].中国分子心脏病学杂志,2023,23(1):5115-5149.DOI:10.16563/j.cnki.1671-6272.2023.02.002.
• [50]Wu Q,Liang Q,Wang R,et al.Transcoronary radiofrequency ablation:a novel septal reduction option for hypertrophic obstructive cardiomyopathy[J].JACC Cardiovasc Interv,2023,16(6):725-726.DOI:10.1016/j.jcin.2022.11.028.
• [51]Long X,Deng S,Liu W,et al.Transcoronary radiofrequency ablation for obstructive hypertrophic cardiomyopathy:a feasibility study[J].Eur Heart J,2024,45(3):233-235.DOI:10.1093/eurheartj/ehad741.
• [52]Zhang C,Yi W,Cai Y,et al.Percutaneous transluminal radiofrequency closure of the coronary artery in animal studies[J].Exp Ther Med,2013,6(4):1044-1048.DOI:10.3892/etm.2013.1262.
• [53]Shelke AB,Menon R,Kapadiya A,et al.A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy[J].Indian Heart J,2016,68(5):618-623.DOI:10.1016/j.ihj.2016.02.007.